543635 and PPLPHARMA. Related Headlines
Go Back- Piramal Pharma Solutions Expands Peptide API Facility with Advanced Spray Drying Suite
- Piramal Pharma Limited Announces Results for Q1 FY27
- Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones
- Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits
- Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development
- Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
- Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing
- Piramal Pharma Solutions' Grangemouth, UK Facility Successfully Delivers 1,500th ADC Batch
- Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities
- Piramal Pharma Limited Announces Results for Q3 and 9M FY26
- Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score
- Piramal Pharma Solutions' Bioconjugates Facility in Grangemouth, UK Receives Updated MHRA GMP Certificates
- Piramal Pharma Limited Announces Results for Q2 and H1 FY26
- Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities
543635 and PPLPHARMA. Related Press Releases
Go Back- Piramal Pharma Solutions Expands Peptide API Facility with Advanced Spray Drying Suite
- Piramal Pharma Limited Announces Results for Q1 FY27
- Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones
- Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits
- Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development
- Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
- Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing
- Piramal Pharma Solutions' Grangemouth, UK Facility Successfully Delivers 1,500th ADC Batch
- Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities
- Piramal Pharma Limited Announces Results for Q3 and 9M FY26
- Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score
- Piramal Pharma Solutions' Bioconjugates Facility in Grangemouth, UK Receives Updated MHRA GMP Certificates
- Piramal Pharma Limited Announces Results for Q2 and H1 FY26
- Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities

